1-13 of 13
Pablo Morentin-Gutierrez
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 3904: Multiplexed flow cytometry based immunophenotyping paired with functional ex vivo (MFLEX) drug profiling informs potential efficacy of therapeutic agents in acute myeloid leukemia

Reecha Shah, Heba Wander, Michelle Hsueh, Muskan Floren, Wei Liu, Patricia Cheung, Courtney Andersen, Michael White, Nathan Kingston, Pablo Morentin Gutierrez, Lisa Drew, Giulia Fabbri, Elena Bibikova, Daniel Auclair
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 3904.
https://doi.org/10.1158/1538-7445.AM2024-3904
Published: 22 March 2024
View article titled, Abstract 3904: Multiplexed flow cytometry based immunophenotyping paired with functional <em>ex vivo</em> (MFLEX) drug profiling informs potential efficacy of therapeutic agents in acute myeloid leukemia
Journal Articles

The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance

Mandy Lawson, Natalie Cureton, Susana Ros, Azadeh Cheraghchi-Bashi, Jelena Urosevic, Sophie D'Arcy, Oona Delpuech, Michelle DuPont, David I. Fisher, Eric T. Gangl, Hilary Lewis, Dawn Trueman, Neha Wali, Stuart C. Williamson, Jennifer Moss, Elodie Montaudon, Heloise Derrien, Elisabetta Marangoni, Ricardo J. Miragaia, Sladjana Gagrica, Pablo Morentin-Gutierrez, Thomas A. Moss, Gareth Maglennon, Daniel Sutton, Radoslaw Polanski, Alan Rosen, Jonathan Cairns, Pei Zhang, Mònica Sánchez-Guixé, Violeta Serra, Susan E. Critchlow, James S. Scott, Justin P.O. Lindemann, Simon T. Barry, Teresa Klinowska, Christopher J. Morrow, Larissa S. Carnevalli
Journal: Cancer Research
Cancer Res (2023) 83 (23): 3989–4004.
https://doi.org/10.1158/0008-5472.CAN-23-0694
Published: 01 December 2023
View article titled, The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER<sup>+</sup> Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance
Open the PDF for The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER<sup>+</sup> Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance in another window
Includes: Supplementary data
Journal Articles

Abstract P3-07-13: The next generation oral selective estrogen receptor degrader (SERD) camizestrant (AZD9833) is active against wild type and mutant estrogen receptor α

Christopher Morrow, Larissa Carnevalli, Richard D. Baird, Tim Brier, Carmela Ciardullo, Natalie Cureton, Mandy Lawson, Robert McEwen, Myria Nikolaou, Anne Armstrong, Begoña Bermejo, Emiliano Calvo, Eva Ciruelos, Javier Garcia-Corbacho, Erika Hamilton, Jason Incorvati, Peter Kabos, Mafalda Oliveira, Manish R Patel, Manuel Ruiz-Borregó, Nicholas Turner, Chris Twelves, Christos Vaklavas, Danielle Carroll, Steven Ching, Nevena Cvetesic, Michelle DuPont, Lisa Gibbons, Alastair Mathewson, Rhiannon Maudsley, Pablo Morentin Gutierrez, Avinash Reddy, Jaime Rodriguez-Canales, Susana Ros, Dhivya Sudhan, Andy Sykes, David Whitson, Teresa Klinowska, Justin Lindemann
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): P3-07-13.
https://doi.org/10.1158/1538-7445.SABCS22-P3-07-13
Published: 01 March 2023
View article titled, Abstract P3-07-13: The next generation oral selective estrogen receptor degrader (SERD) camizestrant (AZD9833) is active against wild type and mutant estrogen receptor α
Journal Articles

Abstract PD10-04: PD10-04 Combination of the next generation oral SERD camizestrant (AZD9833) with CDK4/6 and mTOR/AKT inhibitors delivers robust efficacy in a broad range of ER+ breast tumors

Larissa Carnevalli, Susana Ros, Jelena Urosevic, Natalie Cureton, Sophie Darcy, Mandy Lawson, Stuart Williamson, Pablo Morentin Gutierrez, Azadeh Bashi, Jennifer Moss, Christopher Morrow, Barry Simon, Teresa Klinowska
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): PD10-04.
https://doi.org/10.1158/1538-7445.SABCS22-PD10-04
Published: 01 March 2023
View article titled, Abstract PD10-04: PD10-04 Combination of the next generation oral SERD camizestrant (AZD9833) with CDK4/6 and mTOR/AKT inhibitors delivers robust efficacy in a broad range of ER+ breast tumors
Journal Articles

Abstract 5674: Discovery of AZD9833, an oral small molecule selective degrader of the estrogen receptor (SERD)

James S. Scott, Thomas Moss, Steve Stokes, Willem M. Nissink, Christopher J. Morrow, Mandy Lawson, Natalie Cureton, Eric Gangl, Pablo Morentin Gutierrez, Richard Mather, Justin P. Lindemann, Andrew Sykes, David Fisher, Radoslaw Polanski, Danielle Carroll, Aisling Barton Twomey, Teresa Klinowska
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 5674.
https://doi.org/10.1158/1538-7445.AM2020-5674
Published: 15 August 2020
View article titled, Abstract 5674: Discovery of AZD9833, an oral small molecule selective degrader of the estrogen receptor (SERD)
Journal Articles

Abstract 4369: Preclinical mechanistic PK/PD-efficacy modeling for AZD9833, a novel next generation oral SERD, to support dose selection during early clinical development

Pablo Morentin Gutierrez, Christopher Morrow, Natalie Cureton, Mandy Lawson, Dawn Trueman, Eric Gangl, Joanne Wilson, Aaron Smith, James Scott, Teresa Klinowska
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 4369.
https://doi.org/10.1158/1538-7445.AM2020-4369
Published: 15 August 2020
View article titled, Abstract 4369: Preclinical mechanistic PK/PD-efficacy modeling for AZD9833, a novel next generation oral SERD, to support dose selection during early clinical development
Journal Articles

Abstract 1042: Preclinical pharmacokinetic and metabolic characterization of the next generation oral SERD AZD9833

Eric T. Gangl, Roshini Markandu, Pradeep Sharma, Andy Sykes, Petar Pop-Damkov, Pablo Morentin Gutierrez, James S. Scott, Dermot F. McGinnity, Adrian J. Fretland, Teresa Klinowska
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 1042.
https://doi.org/10.1158/1538-7445.AM2020-1042
Published: 15 August 2020
View article titled, Abstract 1042: Preclinical pharmacokinetic and metabolic characterization of the next generation oral SERD AZD9833
Journal Articles

Abstract 100: Novel selective PI3Kγ inhibitor AZD3458 promotes anti-tumor immune responses and reverts resistance to immunotherapy in checkpoint blockade refractory preclinical models

Larissa S. Carnevalli, Danielle Carrol, Michele Moschetta, Pablo Morentin Gutierrez, Cristina Gardelli, Molly A. Taylor, Antonio Montoya, Adina Hughes, Matthew King, Teresa Klinowska, Simon T. Barry
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 100.
https://doi.org/10.1158/1538-7445.AM2019-100
Published: 01 July 2019
View article titled, Abstract 100: Novel selective PI3Kγ inhibitor AZD3458 promotes anti-tumor immune responses and reverts resistance to immunotherapy in checkpoint blockade refractory preclinical models
Journal Articles

Abstract 104: Mechanistic insights and dose optimization for AZD3458, a novel selective PI3Kg immuno-modulator, using a quantitative systems approach

Pablo Morentin Gutierrez, Yuri Kosinsky, Kirill Peskov, Ivan Azarov, Lulu Chu, Veronika Voronova, Martin Johnson, Yingxue Chen, Larissa Carnevalli, Danielle Carroll, Michele Moschetta, Teresa Klinowska, Gabriel Helmlinger
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 104.
https://doi.org/10.1158/1538-7445.AM2019-104
Published: 01 July 2019
View article titled, Abstract 104: Mechanistic insights and dose optimization for AZD3458, a novel selective PI3Kg immuno-modulator, using a quantitative systems approach
Journal Articles

Abstract 2641: AZD4635 A2A receptor occupancy in cynomolgus monkey using PET and its application to an oncology clinical development program

Peter Johnström, Pablo Morentin Gutierrez, Katarina Varnäs, Magnus Schou, Akihiro Takano, Lorraine Jones, Ganesh Mugundu, Patricia McCoon, Paul Lyne, Jeffrey Infante, Gerald Falchook, Manish Patel, Janet Karlix, Melinda Merchant, James Clarke, Alan Cross, Nicholas Seneca, Lars Farde, Miles Congreve, Jon S. Mason, Fiona H. Marshall
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 2641.
https://doi.org/10.1158/1538-7445.AM2017-2641
Published: 01 July 2017
View article titled, Abstract 2641: AZD4635 A<sub>2A</sub> receptor occupancy in cynomolgus monkey using PET and its application to an oncology clinical development program
Journal Articles

Abstract 4524: A preclinical PKPD modeling & simulation strategy: building a predictive model of dose, schedule and therapeutic index for small molecule targeted anticancer agents

Rhys DO Jones, Rajesh Odedra, James WT Yates, Pablo Morentin Gutierrez, Barry Davies, Kevin Hudson, Simon T. Barry
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 4524.
https://doi.org/10.1158/1538-7445.AM2015-4524
Published: 01 August 2015
View article titled, Abstract 4524: A preclinical PKPD modeling &amp; simulation strategy: building a predictive model of dose, schedule and therapeutic index for small molecule targeted anticancer agents
Journal Articles

Abstract 2668: Applying mechanistic PK/PD modeling to describe the efficacy of AZD8835 (PI3Kalpha/delta inhibitor) in a mouse xenograft breast tumor model at different dosing schedules

Pablo Morentin Gutierrez, Kevin Hudson, Urs J. Hancox, Lara T. Ward, Urszula M. Polanska, Marie Cumberbatch, Francisco H. Cruzalegui
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 2668.
https://doi.org/10.1158/1538-7445.AM2015-2668
Published: 01 August 2015
View article titled, Abstract 2668: Applying mechanistic PK/PD modeling to describe the efficacy of AZD8835 (PI3Kalpha/delta inhibitor) in a mouse xenograft breast tumor model at different dosing schedules
Journal Articles

Abstract 2665: High dose intermittent scheduling of AZD8835, a novel potent and selective inhibitor of PI3Kα and PI3Kδ, identifies potential treatment strategies for PIK3CA-dependent cancers

Kevin Hudson, Urs Hancox, Cath Trigwell, Phillippa Dudley, Lyndsey Hanson, Robert McEwen, Alys Jones, Marie Cumberbatch, Urszula Polanska, Rebecca Ellston, Oona Delpuech, Pablo Morentin Gutierrez, Lara Ward, Francisco Cruzalegui, Stephen Green
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 2665.
https://doi.org/10.1158/1538-7445.AM2015-2665
Published: 01 August 2015
View article titled, Abstract 2665: High dose intermittent scheduling of AZD8835, a novel potent and selective inhibitor of PI3Kα and PI3Kδ, identifies potential treatment strategies for PIK3CA-dependent cancers